#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6232	16S	1529	1529	99.87	16S.l6.c30.ctg.2	2402	588.7	0	.	n	.	0	C451T	SNP	451	451	C	850	850	T	737	T,C,G	664,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6232	16S	1529	1529	99.87	16S.l6.c30.ctg.2	2402	588.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1849	1849	T	770	T,C,G,A	690,3,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6232	16S	1529	1529	99.87	16S.l6.c30.ctg.2	2402	588.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1583	1583	C	760	C,A,G	687,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10866	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4161	625.4	0	.	n	.	0	C331T	SNP	331	331	C	1009	1009	T	781	T,C,A	699,4,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10866	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4161	625.4	0	.	n	.	0	T695C	SNP	695	695	T	1373	1373	C	856	C,T,A,G	755,4,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10866	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4161	625.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2649	2649	C	741	C,A	677,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10866	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4161	625.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2723	2723	A	734	A	657	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10866	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4161	625.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3275	3275	C	808	C,T,G,A	720,4,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	570	folP	852	852	100.0	folP.l15.c4.ctg.1	2044	68.0	1	SNP	p	R228S	0	.	.	682	684	CGC	1314	1316	CGC	95;95;94	C,A;G;C,A	87,1;86;85,1	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1150	gyrA	2751	2751	99.71	gyrA.l15.c4.ctg.1	3943	70.0	0	.	p	.	0	V19I	NONSYN	55	57	GTC	739	741	ATC	81;81;80	A,G;T;C	74,1;73;74	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1150	gyrA	2751	2751	99.71	gyrA.l15.c4.ctg.1	3943	70.0	0	.	p	.	0	S91Y	NONSYN	271	273	TCC	955	957	TAC	86;87;89	T;A,C;C	75;73,1;75	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1150	gyrA	2751	2751	99.71	gyrA.l15.c4.ctg.1	3943	70.0	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1432	1434	ATA	91;91;91	A,T;T,A;A	78,3;79,1;82	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1150	gyrA	2751	2751	99.71	gyrA.l15.c4.ctg.1	3943	70.0	1	SNP	p	D95G	0	.	.	283	285	GAC	967	969	GAC	101;101;101	G;A;C	84;81;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1150	gyrA	2751	2751	99.71	gyrA.l15.c4.ctg.1	3943	70.0	1	SNP	p	D95N	0	.	.	283	285	GAC	967	969	GAC	101;101;101	G;A;C	84;81;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	512	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1887	64.5	0	.	p	.	0	D79N	NONSYN	235	237	GAT	940	942	AAT	102;102;102	A;A;T	93;92;92	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	512	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1887	64.5	1	SNP	p	G45D	0	.	.	133	135	GGC	838	840	GGC	109;109;109	G;G;C	96;96;96	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	316	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1600	47.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1817	1819	GCC	88;87;82	G;C;C	74;75;68	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1859	1861	GCA	82;82;84	G;C;A,C	72;70;69,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	1	SNP	p	D86N	0	.	.	256	258	GAC	812	814	GAC	79;79;79	G;A;C	64;57;67	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	1	SNP	p	S87W	0	.	.	259	261	AGT	815	817	AGT	79;79;90	A,C;G;T,G	62,1;72;78,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	1	SNP	p	S87R	0	.	.	259	261	AGT	815	817	AGT	79;79;90	A,C;G;T,G	62,1;72;78,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	1	SNP	p	S87I	0	.	.	259	261	AGT	815	817	AGT	79;79;90	A,C;G;T,G	62,1;72;78,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1092	parC	2304	2304	99.65	parC.l6.c4.ctg.1	3371	77.8	1	SNP	p	S88P	0	.	.	262	264	TCC	818	820	TCC	90;88;88	T;C,T;C	75;75,1;80	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1030	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3308	75.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1892	1894	GGC	93;94;94	G;G,A;C	82;79,1;78	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1619	1621	GCA	159;160;159	G,C;C,A;A	143,1;144,1;144	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1622	1624	ATC	160;160;160	A;T,G;C,A	144;144,1;141,1	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1634	1636	GTG	160;159;159	G,T;T;G,A	144,1;142;142,1	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1634	1636	GTG	160;159;159	G,T;T;G,A	144,1;142;142,1	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	2135	2137	ACC	82;82;82	A;C;C,T	64;66;71,1	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2189	2191	GCG	84;84;84	G,T;C,G;G	64,1;67,1;64	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2189	2191	GCG	84;84;84	G,T;C,G;G	64,1;67,1;64	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2312	2314	GGC	76;76;76	G;G,T;C,T	76;75,1;75,1	penA.0.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2321	2323	GGC	66;65;63	G,A;G;C	65,1;61;52	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1092	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2876	89.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2339	2341	CCG	60;58;58	C;C,G;G	55;52,1;56	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1940	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	3489	129.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	574	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2321	58.9	0	.	p	.	0	S22G	NONSYN	64	66	AGC	661	663	GGC	54;54;56	G,A,C;G;C,G	44,1,2;46;48,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	574	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2321	58.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	843	843	C	64	C	53	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	A29V	NONSYN	85	87	GCC	615	617	GTC	120;120;120	G;T,A;C	111;107,1;109	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	T50A	NONSYN	148	150	ACT	678	680	GCT	106;108;110	G;C;T,A	97;99;98,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	K88L	NONSYN	262	264	AAA	792	794	CTC	114;114;114	C,G,A;T,G;C,A,T	99,2,1;98,7;101,1,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	S93N	NONSYN	277	279	AGC	807	809	AAC	107;107;107	A;A,C;C	86;80,1;95	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	H111R	NONSYN	331	333	CAT	861	863	CGT	89;89;93	C;G;T,C	84;84;86,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	N114S	NONSYN	340	342	AAC	870	872	AGC	94;94;91	A,G;G,C;C	88,1;81,1;84	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	I115V	NONSYN	343	345	ATC	873	875	GTC	92;100;102	G;T,C;C	87;91,1;95	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	D120G	NONSYN	358	360	GAC	888	890	GGC	103;105;104	G;G;C	93;97;95	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	1131	1133	TTC	98;98;97	T;T;C	93;92;91	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	628	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	2195	67.3	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1236	1238	CGC	85;85;85	C;G;C	77;75;76	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	3122	rpoB	4179	4179	99.93	rpoB.l6.c4.ctg.1	5632	132.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2474	2476	CAT	161;161;161	C,T,A;A,T;T	140,2,1;141,2;144	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	492	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1594	74.7	1	SNP	p	V57M	1	.	.	169	171	ATG	806	808	ATG	173;172;176	A;T;G	152;155;157	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
